Allosig

Quick links to important sections

Allosig

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Allosig

Property Description
Active Ingredient Allopurinol
Form Oral Tablet (often scored)
Pharmacological Class Xanthine Oxidase Inhibitor (XOI)
Origin Synthetic Compound (Purine Analogue)
General Purpose Reduction of Uric Acid Production

Allosig is a prescription-only medicine designed for the long-term control of conditions associated with chronically high levels of uric acid in the bloodstream. It is a single-ingredient product whose active chemical substance is Allopurinol. This medication belongs to the pharmacological class of Xanthine Oxidase Inhibitors (XOI), a specific type of uricosuppressive agent used in chronic therapy. Allopurinol functions to decrease high blood uric acid levels, an approach that is clinically recognized for managing the underlying metabolic condition and is supported by pharmacological principles.


Composition, Form, and General Purpose

The core of the Allosig formulation is the active ingredient Allopurinol, a synthetic compound chemically known as 4-hydroxypyrazolo(3,4-d)pyrimidine. The medication is presented as an oral formulation in the form of a tablet, often a scored tablet, allowing for flexible and precise adjustment of the maintenance dose, which is critical for effective chronic therapy. The use of a scored tablet, a feature emphasized for dose accuracy, facilitates compliance in adult patient groups requiring consistent daily intake.

The overarching function of the medicine is to achieve a sustained reduction in the concentration of serum urate levels by directly inhibiting the enzyme xanthine oxidase. Allopurinol is classified by its ability to inhibit this key enzyme, meaning the drug's fundamental mechanism blocks the metabolic pathway responsible for creating uric acid in the body. The resulting decrease in uric acid production is the drug's general therapeutic purpose, forming the basis for long-term management in scenarios such as preventing the recurring crystallization of urate.

Regulatory References

  1. Allopurinol: MedlinePlus Drug Information

What side effects are possible with Allosig?

Possible Side Effects and Safety Information

The safety profile of Allosig (Allopurinol) is classified by official regulatory authorities based on the frequency and nature of documented adverse reactions. These classifications reflect how government bodies organize and communicate the medicine’s risk profile, focusing on various physiological systems.

Frequency-Classified Adverse Reactions

The most common documented adverse reaction is skin rash, which is noted in regulatory documents as the most frequently occurring event. Uncommon effects include signs of hypersensitivity reactions, gastrointestinal issues such as vomiting and abdominal discomfort, and asymptomatic, transient increases in liver enzymes.

Serious and Systemic Safety Concerns

Rare and very rare serious adverse events are documented across several organ systems. The most critical safety concern is the occurrence of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. Other rare, severe events include blood dyscrasias (e.g., agranulocytosis) and hepatitis.

Population-Specific Safety Notes

Official labeling specifies altered risk for certain groups. Individuals with impaired renal function face an increased risk of toxicity and adverse reactions due to the accumulation of the medicine. Furthermore, the risk of SCARs is officially documented as being higher in patients of specific Asian descent (e.g., Han Chinese, Korean, or Thai) who carry the HLA–B 5801 allele.

Exposure-Related Safety Patterns

Hypersensitivity reactions, including rash, are documented as more frequent during the initial phase of therapy or when the dose is being increased. Safety-related restrictions mandate a substantial dose reduction of concomitant medicines, such as azathioprine or mercaptopurine, to mitigate the documented potential for myelosuppression.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile of Allosig (Allopurinol) based on documented manifestations and mandated emergency actions.

Documented Overdose Manifestations

Acute massive overdose has been reported to primarily affect the gastrointestinal and nervous systems. Documented presentations include nausea, vomiting, diarrhea, and dizziness. Other associated findings listed in regulatory guidance include headaches and stomach pain.

Severe Outcomes and Emergency Action

Overdose or severe drug accumulation, particularly in individuals with impaired renal function, carries the risk of life-threatening systemic reactions, such as Stevens-Johnson syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). These severe outcomes require immediate intervention.

Emergency medical attention must be sought immediately following any suspected overdose or at the first sign of a severe skin rash, as mandated by regulatory authorities. Management is based on general supportive measures, including ensuring adequate hydration to maintain optimum diuresis, which facilitates the excretion of allopurinol and its metabolites. No specific antidote is known for Allopurinol overdose. The drug and its metabolites are removable by renal dialysis, which may be a consideration in severe toxicity.

Therapeutic Uses of Allosig

What Allosig Treats: Main Uses and Benefits

Allosig is generally used for managing conditions characterized by periods of heightened symptoms related to systemic imbalance. Its primary role is to provide supportive relief across domains where additional symptomatic support is needed, assisting with maintaining functional stability during episodes of discomfort. This medicine is used for managing conditions and symptom patterns in line with its approved therapeutic domains.


Key Areas of Symptom Management

Allosig is applicable within clinical settings that involve acute or disruptive symptom patterns, and is often used during phases when symptoms become more noticeable. It helps address symptom clusters that may become intense or disruptive in conditions presenting with recurrent or episodic manifestations, including those involving systemic or localized discomfort and symptoms associated with acute or episodic changes.

This medication is relevant for conditions involving episodic or fluctuating manifestations where symptoms create noticeable physiological strain. It contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Physiological Strain

Allosig is applied when symptoms create noticeable physiological strain, assisting with maintaining a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

This medicine is an allopurinol-containing product, and its eligibility for use is strictly defined by regulatory documents. It is primarily intended for adult patients with signs and symptoms of gout, recurrent kidney stones (calcium oxalate calculi with hyperuricosuria), or high uric acid levels due to cancer therapy.

Populations Who Must Not Use Allosig (Contraindications)

  • Individuals with a known hypersensitivity or severe allergic reaction to allopurinol or any of the product's components.
  • Patients with haemochromatosis (excessive iron storage) who are concurrently taking iron salts.

Use Restrictions and Special Considerations

  • Pediatric Use: Use in children under 15 is rarely indicated and is typically limited to specific, severe conditions such as certain enzyme disorders (e.g., Lesch-Nyhan syndrome) or malignancies, especially leukemia.
  • Renal and Hepatic Function: Patients with impaired kidney or liver function require reduced doses and careful professional monitoring, as the drug and its active metabolite are primarily cleared through the kidneys.
  • Lactation: Use is not recommended while breastfeeding.
  • Asymptomatic Hyperuricemia: The medicine is not recommended for the treatment of high uric acid levels that are not causing any symptoms.

What should I know about interactions with other medicines?

Allosig Interactions with other medicines and products

Allosig (allopurinol) has specific documented interactions with certain medicinal products, primarily due to its role as a xanthine oxidase inhibitor.

Interacting Product Category Clinical Impact & Requirement
Mercaptopurine / Azathioprine Major Interaction: Allosig inhibits the metabolism of these purine analogs, significantly increasing their concentration. Concomitant use requires a substantial dose reduction (typically to one-third or one-fourth) of mercaptopurine or azathioprine to avoid severe toxicity, such as bone marrow suppression.
Capecitabine Contraindicated Combination: Concomitant use should be avoided. Allosig may decrease the efficacy of capecitabine, a chemotherapy drug, by suppressing the phosphorylation of its active metabolite.
Pegloticase Avoid Combination: Allosig therapy must be discontinued before initiating treatment with Pegloticase, an enzyme for chronic gout.
Oral Anticoagulants (e.g., Warfarin) Allosig may enhance the anticoagulant effect. Close monitoring of blood clotting time (prothrombin time/INR) and potential dose adjustment of the anticoagulant are necessary.
Thiazide Diuretics Concomitant use, especially in patients with impaired kidney function, may increase the risk of serious hypersensitivity reactions (e.g., severe skin rash).
Penicillin-Class Antibiotics Co-administration with ampicillin or amoxicillin may increase the frequency of skin rash.

These interactions necessitate careful review and potential medication adjustment. Patients with existing renal impairment are noted to be at an increased risk for severe hypersensitivity reactions with certain combinations.

Mechanism of Action

How Allosig Works

Allosig (Allopurinol) operates through a targeted metabolic blockade, resulting in the sustained suppression of a key purine end-product. Its mechanism of action is confined to molecular pathways that govern the body's internal synthesis processes.

The drug functions by inhibiting the enzyme Xanthine Oxidase (XO), a biological target crucial for the final stages of purine catabolism. By binding to this enzyme, the drug prevents the conversion of purine precursors into uric acid (urate), directly resulting in a systemic reduction in the concentration of uric acid.

The sustained duration of the effect is achieved by the drug's conversion into the active metabolite, Oxypurinol. This metabolite facilitates a dual-action inhibition where Oxypurinol provides a highly stable, long-lasting inactivation of the XO enzyme. This mechanism facilitates the consistent maintenance of low urate concentrations, resulting in a gradual physiological consequence.

The sustained lowering of serum urate concentration creates a favorable metabolic gradient. This gradient establishes the thermodynamic force that governs the gradual dissolution and mobilization of pre-existing urate deposits found in tissues and joints. This slow process of crystal mobilization is a direct physiological consequence of the drug's sustained XO inhibition.

Dosage and Administration Information

Allosig (Allopurinol) is administered primarily via the oral route as a tablet for chronic, long-term therapeutic control. The medication is also approved as a powder for intravenous (IV) infusion for specific acute conditions, such as malignancy-associated hyperuricemia, in patients who are unable to take the medicine orally.

Oral therapy follows a principle of gradual titration. The typical adult starting dose is 100 mg once daily. The maintenance dosage ranges from 200 mg to 600 mg per day, depending on the patient's response, but must not exceed the maximum daily limit of 800 mg. For any total daily dose greater than 300 mg, the dose must be taken in divided portions throughout the day to ensure proper absorption and tolerability.

Oral tablets should be taken immediately after meals and with a full glass of water. A critical requirement during therapy is maintaining adequate fluid intake to ensure a urinary output of at least two liters per day. If a dose is missed, patients are strictly instructed not to double the next scheduled dose. Furthermore, patients with impaired kidney function require mandated reductions in the starting and maintenance dose according to the specific level of renal impairment. If the IV form is used, the reconstituted product must be diluted to a final concentration that does not exceed 6 mg/mL before being administered as an infusion.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Allosig

This section provides an overview of the research evidence and clinical trials that have been conducted to evaluate Allosig (Allopurinol), drawing on authoritative sources to describe what was studied and what the findings reported. This is a descriptive summary and does not offer any clinical guidance or recommendations.

Research Evidence for Hyperuricemia and Gout

The core research for Allosig primarily involves Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that combine the data from multiple trials. These studies were used in research exploring how to achieve and maintain low concentrations of serum urate in the bloodstream, which was evaluated in studies relevant to the long-term management of conditions like gout. The populations evaluated were typically adults with a diagnosis of gout, including individuals who also had uric acid deposits, known as tophi.

Study Endpoints: Focus on Urate Levels and Exacerbations

The main outcomes studied in these trials centered on measuring biomarker shifts, specifically tracking the change in serum urate (SUA) levels. Researchers evaluated whether the studied populations reached and sustained a specific target concentration. Researchers also used this research exploring how symptoms change over time, monitoring clinical endpoints such as the frequency of gout flares—outcomes related to episodic or acute changes. In studies involving patients with tophi, research examined whether the tophi dissolved or showed reduction in size over the defined study intervals. Studies report how symptoms evolved in the observed populations, indicating patterns observed in the studies related to achieving the required urate target.


Research into Outcomes Beyond Uric Acid Control

In addition to its primary use, Allosig was evaluated in studies exploring outcomes related to systemic or functional imbalance, specifically focusing on cardiovascular and kidney-related health markers. This research includes Systematic Reviews and large-scale Observational Cohort Studies. These studies monitored populations that often have high uric acid alongside other conditions, such as high blood pressure (hypertension) or existing Chronic Kidney Disease (CKD).

Limitations, Gaps, and What Remains Uncertain in the Evidence

The research provides a framework for understanding the evaluation of high uric acid levels, but several limitations and gaps exist. Follow-up durations were limited in many initial controlled trials, meaning long-term outcomes are not fully established for all patients. Data for certain groups, such as those with certain comorbidities or advanced CKD, remain insufficient for strong conclusions. Furthermore, evidence quality varies across studies, and comparative evidence against certain other urate-lowering therapies is lacking for certain long-term clinical endpoints like cardiovascular risk. Research is ongoing to better understand these outcomes, and study results reflect the specific conditions under which they were conducted, not guaranteeing personal outcomes.

Key Studies & References

  1. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout
  2. Effectiveness of Allopurinol on Uric Acid and Pediatric Chronic Kidney Disease Severity in the Chronic Kidney Disease in Children Study (Observational)
  3. Effect of allopurinol on the treatment of chronic kidney disease: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Allosig (FAQ)

Q: Is Allosig used to treat an active gout attack?

A: According to official product information, Allosig is primarily used for the long-term prevention of gout attacks, not for treating an active flare once it has started. Prophylaxis with other medications is often described as a strategy when initiating treatment to help prevent initial flares.

Q: Is it common to have more gout attacks right after starting Allosig?

A: Official product information indicates that gout flares may occur shortly after starting treatment due to changes in the body's uric acid levels as the medication begins to work. For this reason, an anti-inflammatory medicine is often described as being used alongside Allosig during the initial phase.

Q: How soon after starting Allosig will my uric acid levels drop?

A: Pharmacological data describes a reduction in uric acid levels typically occurring within 2 to 3 days of initiation. The full observed effect of a specific dosage is established over a week or more of treatment.

Q: What should I look out for if I have kidney or liver issues while on Allosig?

A: Official labeling states that dose adjustments and careful professional monitoring are indicated for individuals with impaired kidney or liver function. Official documents advise that signs of a serious adverse event, such as changes consistent with liver issues (e.g., yellow skin or eyes) or kidney issues (e.g., significant change in urination), be reported to a healthcare provider.

Q: How does Allosig interact with certain chemotherapy drugs?

A: Official labeling includes specific warnings regarding interactions with chemotherapy. Use with mercaptopurine or azathioprine necessitates a substantial dose reduction of the chemotherapy agent. The combination with capecitabine is described in official documents as being one that should be avoided.

Q: Is Allosig generally considered safe for older adults?

A: The drug is used in adults. However, patients with impaired kidney function (which is common in the elderly) require lower starting and maintenance doses. The need for dose adjustment, based on an individual's specific renal function, is noted in the official prescribing information.

Q: How often should blood tests be done while taking Allosig?

A: Regular monitoring of serum urate levels and blood counts is part of routine management. Clinical guidelines referenced in official literature often describe monitoring serum urate levels every 2 to 5 weeks during dose titration and periodically during maintenance therapy.

Q: Is there a way to lessen the nausea or stomach upset caused by Allosig?

A: Nausea and stomach upset are listed as potential side effects. Official product information describes the administration of Allosig immediately after a meal with a full glass of water to ensure proper absorption and to help with tolerability.

Q: Does Allosig affect the action of certain antibiotics?

A: Co-administration with penicillin-class antibiotics, specifically ampicillin or amoxicillin, is associated with an increased frequency of skin rash. All concurrent prescriptions are noted as needing review by a healthcare provider.

Q: Is there a version of Allosig available for children?

A: The oral tablet form is not generally indicated for children. Use in children under 15 is typically reserved for specific, severe conditions, such as certain enzyme disorders or high uric acid levels related to cancer treatment, as determined by a specialist.

Q: Is there a maximum recommended daily amount of Allosig?

A: Official regulatory documents specify the maximum allowable dosage. The maximum daily dose of the oral tablet formulation should not exceed 800 mg for adults.

Q: Can Allosig be used for purposes other than gout and kidney stones?

A: In addition to gout and certain kinds of kidney stones, Allosig is also officially approved for the prevention of tumor lysis syndrome. This is a high uric acid condition that can occur as a complication of certain cancer treatments.

Q: What happens if I stop taking Allosig suddenly?

A: There is no physiological withdrawal syndrome if the medication is stopped abruptly. Cessation of treatment can lead to the return of high uric acid levels, which is associated with the potential for a recurrence of hyperuricemia and gout flares.

Q: Does Allosig actually break up the existing gout crystals in my joints?

A: The medicine works indirectly on existing deposits. Official documents describe the mechanism as promoting the gradual dissolution and mobilization of pre-existing urate deposits (crystals) by maintaining a low concentration of uric acid in the bloodstream.

Q: Is feeling drowsy or dizzy common when taking Allosig?

A: Official safety information indicates that Allosig may cause some people to become drowsy, dizzy, or less alert than usual. Because the medicine may cause some people to become drowsy or dizzy, caution is noted as being necessary when performing activities that require alertness.

Q: Are there any dietary restrictions or foods to avoid while taking Allosig?

A: While the drug label does not strictly contraindicate specific foods, the effective management of high uric acid often includes broader lifestyle and dietary changes. The need for reduction in the intake of dietary sodium, animal protein, and oxalate-rich foods is described in official information regarding the management of high uric acid.

Q: Does taking Vitamin C or other supplements affect how Allosig works?

A: Specific testing on most vitamins, supplements, and herbal remedies with Allosig has not been extensively documented. Due to limited testing, official sources suggest informing a healthcare provider about all vitamins, supplements, and herbal remedies being taken.

Q: Can Allosig be taken with other prescriptions for heart conditions?

A: Allopurinol interacts with certain medications commonly used for heart conditions, including some diuretics (water pills) and the anticoagulant warfarin (a blood thinner). Because interactions are documented, all concurrent prescriptions are noted as needing review by a healthcare provider.

Q: Does Allosig affect medications for high blood pressure?

A: Yes, the product label confirms interactions with certain high blood pressure medications, such as thiazide diuretics and ACE inhibitors. The official information states that potential dose adjustments may be required.

Q: Can Allosig be taken with the gout flare treatment Colchicine?

A: Yes, Allosig is often used alongside colchicine or an anti-inflammatory agent, as described in regulatory documents, to help prevent gout flares when initiating therapy.

Q: What is known about taking Allosig during pregnancy?

A: Safety has not been established for use during pregnancy. Regulatory bodies generally do not recommend using the medication while pregnant unless the potential benefit is determined to outweigh the potential risk to the fetus.

Q: Is Allosig similar to Febuxostat? (Common user comparison question)

A: Both are prescription drugs used for urate-lowering therapy in the management of gout. Febuxostat is sometimes used as an alternative for patients who are unable to tolerate Allosig due to adverse effects.

Q: What is the usual recommended target uric acid level for patients taking Allosig?

A: Clinical guidelines often describe the goal of titration as achieving a target serum urate level of less than 6 mg/dL (360 µmol/L) for most gout patients under long-term management.

Q: Is the active ingredient in Allosig the same as Zyloprim?

A: Yes. Allosig contains the active ingredient allopurinol, and Zyloprim is a common brand name for the same active chemical substance.

Q: Can Allosig affect a person's mood or cause anxiety?

A: Comprehensive adverse reaction data documents that side effects related to mood are rare. Anxiety, agitation, and depression are listed as potential rare effects of the medication.

How should Allosig be stored and disposed of?

Storage Conditions

Allosig (allopurinol tablets) must be stored at Controlled Room Temperature, specifically maintained between 20 C to 25 C (68 F to 77 F). The medication should be kept in its original, tightly closed container to preserve product stability.

Environmental Protection and Child Safety

It is required to store the tablets away from moisture and excessive heat. As with all prescription medications, Allosig must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Unused or expired Allosig should be disposed of through a dedicated medicine take-back program when available. The tablets must not be flushed down the toilet or poured down a drain. If a take-back program is inaccessible, the medication should be mixed with an unpalatable substance and sealed before being placed in the household trash, after scratching out all identifying information on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Allosig found in:

A-Z Index: